- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03101735
Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece (FIDELITY)
July 27, 2021 updated by: Genesis Pharma CNS & Specialty
A Real Life, Non-interventional, Multicentre Study to Assess Resource Utilization and Quality of Life of Patients With Relapsing Forms of Multiple Sclerosis Treated With Dimethyl Fumarate in Greece - the FIDELITY Study
This is a non interventional, multicenter clinical trial, in adult patients receiving Tecfidera per approved SmPC and routine clinical practice.
The primary objective of this study is to evaluate the total societal costs to the healthcare system related to the use of Tecfidera in RRMS patients.
The study will capture data in a simple matter that can be easily interpreted providing an advantage in a country where efforts in the market access arena are in their infancy.
For the aforementioned reasons, the proposed study may prove quite valuable in supporting DMF as a cost-effective therapy, valuable not only for patients but for the public health care system as well, providing all the necessary information for the evaluation that need to be examined regarding the positive reimbursement list and future decisions.
Study Overview
Detailed Description
The study will take place in Greece.
Investigators will participate from a broad geographical distribution in order to ensure a proper representation from all areas of Greece.
Investigator's decision to prescribe DMF (Tecfidera®) (according to the indication for treatment as defined in the summary of product characteristics, SmPC and the current clinical practice), should precede entry into the study.
Study Type
Observational
Enrollment (Actual)
455
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Thessaloniki, Greece, 54636
- University General Hospital AHEPA (B')
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 63 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
400 previously DMF-naïve adult patients who have been diagnosed with RRMS and will initiate treatment with Dimethyl Fumarate up to 1 week before study enrolment will be included
Description
Inclusion Criteria:
- Persons aged 18-65 years.
- Patients with a confirmed diagnosis of RRMS.
- Patients for whom the decision to prescribe therapy with Tecfidera®, according to the locally approved product's summary of product characteristics (SmPC) has already been taken prior to their enrolment in the study. The assignment of a patient to this therapeutic strategy is not decided in advance, but falls within current practice, while the prescription of Tecfidera® is clearly separated from the physician's decision to include the patient in the current study.
- Patients must have signed an informed consent document.
- Patients must be able to read, understand and complete the study specific questionnaire.
Exclusion Criteria:
- Patients having other forms of MS, like Clinically Isolated Syndrome (CIS) or progressive forms.
- Patients who have initiated treatment with Tecfidera® more than 7 days before study enrolment or have received DMF at any different time prior to this period.
- Patients that meet any of the contraindications to the administration of the study drug according to the approved SmPC.
- Receipt of any investigational agent within 30 days or 5 half-lives of the investigational agent (whichever is longer) before the commencement of therapy with Tecfidera®.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Cost
Time Frame: The primary outcome measure will be assessed at 6, 12, 18 and 24 months post recruitment. The data that will be presented is the total societal costs to the healthcare system related to the use of Tecfidera.
|
The primary endpoint of this study is the total cost, at the end of the study, of treatment, of the utilization of healthcare services, and of personal expenses associated with RRMS in patients receiving Dimethyl Fumarate.
|
The primary outcome measure will be assessed at 6, 12, 18 and 24 months post recruitment. The data that will be presented is the total societal costs to the healthcare system related to the use of Tecfidera.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 23, 2016
Primary Completion (Actual)
April 23, 2020
Study Completion (Actual)
April 23, 2020
Study Registration Dates
First Submitted
March 3, 2017
First Submitted That Met QC Criteria
March 29, 2017
First Posted (Actual)
April 5, 2017
Study Record Updates
Last Update Posted (Actual)
July 28, 2021
Last Update Submitted That Met QC Criteria
July 27, 2021
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIS-GEN-DMF-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on RRMS
-
Novartis PharmaceuticalsCompletedMultiple Sclerosis | RRMSSpain, Czechia, Germany, Australia, Italy, Switzerland, Denmark, United States, United Kingdom, Canada, Netherlands, Poland
-
BayerCompletedRelapsing Remitting Multiple Sclerosis (RRMS)China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
-
Novartis PharmaceuticalsCompletedRelapsing Remitting Multiple Sclerosis RRMSGermany, Switzerland
-
Novartis PharmaceuticalsTerminatedRelapsing-remitting Multiple Sclerosis (RRMS)United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
-
GE HealthcareCentre for Probe Development and CommercializationCompletedRelapsing-remitting Multiple Sclerosis (rrMS)Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | RRMSRussian Federation, Ukraine, Czech Republic
-
BiogenRecruiting
-
BayerCompletedRelapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
-
Immunic AGActive, not recruitingRelapsing-Remitting Multiple Sclerosis (RRMS)Poland, Bulgaria, Romania, Ukraine
-
BiogenAbbVieTerminatedRelapsing-Remitting Multiple Sclerosis (RRMS)Italy, United States, Canada, Germany, Puerto Rico
Clinical Trials on Dimethyl Fumarate (DMF)
-
Almirall, S.A.Completed
-
BiogenCompletedRelapsing Forms of Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis, Relapsing-RemittingPoland, Turkey, United States, Latvia, Lebanon, Germany, Belgium, Bulgaria, Czechia, Kuwait
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisFrance, Italy, Spain, Czechia, Hungary, Austria, Belgium, Canada, Portugal, Slovakia, Slovenia
-
BiogenCompletedMultiple Sclerosis, Relapsing-RemittingPoland, Belgium, Turkey, Bulgaria, United States, Czechia, Germany, Kuwait, Latvia, Lebanon
-
BiogenCompletedMultiple Sclerosis, Relapsing-RemittingItaly
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisGermany
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisKorea, Republic of, Taiwan, Czechia, Japan, Poland
-
BiogenCompletedMultiple Sclerosis | Multiple Sclerosis, Relapsing-RemittingUnited States, Bulgaria, Belgium, Poland, Lithuania, Kuwait, Turkey
-
BiogenCompleted